Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | SLC6A5 | Q9Y345 | 12/20 | 0.72 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017789 | 0.85 | TP53 (1.00) | TP53SLC6A5HTR2AP2RX3TDP1 | |
| SCHEMBL5022323 | 0.84 | SLC6A5 (1.00) | TP53SLC6A5HTR2AP2RX3LMNA | |
| SCHEMBL5017350 | 0.84 | TP53 (0.75) | TP53SLC6A5HTR2AP2RX3TDP1 | |
| SCHEMBL5015969 | 0.83 | SLC6A5 (1.00) | TP53SLC6A5HTR2AP2RX3OPRM1 | |
| SCHEMBL2292348 | 0.83 | TP53 (0.77) | TP53SLC6A5HTR2AP2RX3LMNA | |
| SCHEMBL5025990 | 0.82 | TP53 (0.75) | TP53SLC6A5HTR2AP2RX3LMNA | |
| SCHEMBL5015981 | 0.82 | SLC6A5 (1.00) | TP53SLC6A5HTR2AP2RX3L3MBTL1 | |
| SCHEMBL5017983 | 0.81 | TP53 (0.81) | TP53SLC6A5HTR2AP2RX3LMNA | |
| SCHEMBL5022643 | 0.80 | SLC6A5 (1.00) | TP53SLC6A5HTR2AP2RX3LMNA | |
| SCHEMBL5018000 | 0.80 | TP53 (0.79) | TP53SLC6A5HTR2AP2RX3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419138-B1 | N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL BENZAMIDE DERIVATIVES | ORGANON NV (NL) | 2008-10-29 | — | — | EP | disclosed |
| US-7126027-B2 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | AKZO NOBEL N.V. (NL) | 2006-10-24 | — | — | US | disclosed |
| US-20040242685-A1 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | N.V. ORGANON (NL) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242685-A1 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | SLC1A2, SLC6A1, KCNT2 | TP53 4820/4885SLC6A5 26/4885HTR2A 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.